Introduction

This page provides a comprehensive analysis of the known insider trading history of Flaherty Keith T.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Flaherty Keith T. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:KNTE / Kinnate Biopharma Inc. Director 0
US:CMPI / Checkmate Pharmaceuticals Inc Director 0
US:CLVS / Clovis Oncology Inc Director 42,223
US:LOXO / Loxo Oncology, Inc. Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Flaherty Keith T.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Flaherty Keith T. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-04-05 2024-04-03 4 KNTE Kinnate Biopharma Inc.
Common Stock
D - Sale to Issuer -66,377 0 -100.00
2022-05-31 2022-05-31 4 CMPI Checkmate Pharmaceuticals, Inc.
Stock Option (Right to Buy)
D - Sale to Issuer -22,736 0 -100.00
2022-05-31 2022-05-31 4 CMPI Checkmate Pharmaceuticals, Inc.
Stock Option (Right to Buy)
D - Sale to Issuer -4,012 0 -100.00
2022-05-31 2022-05-31 4 CMPI Checkmate Pharmaceuticals, Inc.
Stock Option (Right to Buy)
D - Sale to Issuer -10,030 0 -100.00
2021-06-21 2021-06-16 4 CMPI Checkmate Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 10,030 10,030
2021-06-14 2021-06-11 4 KNTE Kinnate Biopharma Inc.
Stock Option (right to buy)
A - Award 20,250 20,250
2021-06-11 2021-06-10 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 42,223 42,223
2020-12-02 3 KNTE Kinnate Biopharma Inc.
Common Stock
66,377
2020-06-05 2020-06-04 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 40,138 40,138
2019-06-07 2019-06-06 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 28,882 28,882
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -8,750 0 -100.00 235.00 -2,056,250
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -2,500 0 -100.00 235.00 -587,500
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -11,000 0 -100.00 235.00 -2,585,000
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -7,812 0 -100.00 235.00 -1,835,820
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -7,812 0 -100.00 235.00 -1,835,820
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -12,500 0 -100.00 235.00 -2,937,500
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -15,625 0 -100.00 235.00 -3,671,875
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -31,459 0 -100.00 235.00 -7,392,865
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -68,620 0 -100.00 235.00 -16,125,700
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -32,345 0 -100.00 235.00 -7,601,075
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Common Stock
D - Sale to Issuer -9,732 0 -100.00 235.00 -2,287,020
2018-10-15 2018-10-11 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 14,770 14,770
2018-06-14 2018-06-13 4 LOXO Loxo Oncology, Inc.
Director Stock Option (right to buy)
A - Award 8,750 8,750
2018-06-11 2018-06-07 4 LOXO Loxo Oncology, Inc.
Director Stock Option (right to buy)
M - Exercise -50,000 32,345 -60.72
2018-06-11 2018-06-07 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale -5,422 9,732 -35.78 175.97 -954,116 1,712,552
2018-06-11 2018-06-07 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale -4,743 15,154 -23.84 175.10 -830,501 2,653,471
2018-06-11 2018-06-07 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale -16,037 19,897 -44.63 174.04 -2,791,153 3,462,965
2018-06-11 2018-06-07 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale -12,243 35,934 -25.41 173.32 -2,121,981 6,228,153
2018-06-11 2018-06-07 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale -4,634 48,177 -8.77 172.03 -797,209 8,288,121
2018-06-11 2018-06-07 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale -5,021 52,811 -8.68 171.15 -859,359 9,038,761
2018-06-11 2018-06-07 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale -1,900 57,832 -3.18 169.85 -322,707 9,822,522
2018-06-11 2018-06-07 4 LOXO Loxo Oncology, Inc.
Common Stock
M - Exercise 50,000 59,732 513.77 1.18 59,200 70,723
2018-01-05 2018-01-04 4 LOXO Loxo Oncology, Inc.
Director Stock Option (right to buy)
A - Award 2,500 2,500
2017-11-22 2017-11-20 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -1,961 9,732 -16.77 77.33 -151,648 752,596
2017-11-22 2017-11-20 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -800 11,693 -6.40 76.29 -61,032 892,059
2017-11-22 2017-11-20 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -4,489 12,493 -26.43 75.35 -338,241 941,334
2017-08-23 2017-08-21 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -3,450 16,982 -16.89 72.65 -250,629 1,233,674
2017-08-23 2017-08-21 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -3,800 20,432 -15.68 71.91 -273,255 1,469,247
2017-06-23 2017-06-22 4 LOXO Loxo Oncology, Inc.
Director Stock Option (right to buy)
A - Award 11,000 11,000
2017-06-08 2017-06-08 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2017-05-24 2017-05-22 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -110 24,232 -0.45 46.24 -5,086 1,120,400
2017-05-24 2017-05-22 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -2,799 24,342 -10.31 45.75 -128,049 1,113,600
2017-05-24 2017-05-22 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -4,341 27,141 -13.79 44.64 -193,801 1,211,694
2017-02-23 2017-02-21 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -7,250 31,482 -18.72 41.45 -300,517 1,304,948
2016-12-21 2016-12-19 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -7,250 38,732 -15.77 30.23 -219,168 1,170,868
2016-09-09 2016-09-07 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -14,500 45,982 -23.97 30.00 -435,000 1,379,460
2016-08-12 2016-08-11 4 LOXO Loxo Oncology, Inc.
Common Stock
S - Sale X -15,000 60,482 -19.87 26.00 -389,967 1,572,399
2016-06-13 2016-06-10 4 LOXO Loxo Oncology, Inc.
Director Stock Option (right to buy)
A - Award 7,812 7,812
2016-06-10 2016-06-09 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2015-07-30 2015-07-28 4 LOXO Loxo Oncology, Inc.
Director Stock Option (right to buy)
A - Award 7,812 7,812
2015-06-15 2015-06-11 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2014-12-23 2014-12-19 4 LOXO Loxo Oncology, Inc.
Director Stock Option (right to buy)
A - Award 12,500 12,500
2014-08-01 2014-07-31 4 LOXO Loxo Oncology, Inc.
Director Stock Option (right to buy)
A - Award 15,625 15,625
2014-07-31 3 LOXO Loxo Oncology, Inc.
Common Stock
150,964
2014-07-31 3 LOXO Loxo Oncology, Inc.
Common Stock
150,964
2014-06-16 2014-06-12 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 12,414 12,414
2013-06-14 2013-06-13 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 27,587 27,587
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)